Product Information
PROGRAF 0.2 MG GRANULE PACKET is a brand product labeled by Astellas Pharma US, Inc., priced at $5.0151 per EA under NDC 00469123050. Its NADAC has been published 81 times since Mar 19, 2025.
FDA first approved this application on May 24, 2018.
The High Outlier badge above means this manufacturer's average price in the Tacrolimus market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.2 mg/1
Manufacturer
Astellas Pharma US, Inc.NDC
00469123050
Classification
Brand
Dosage Form
GRANULE, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TACROLIMUSApproval Type
New Drug (NDA)
FDA Application
NDA210115FDA Approved
5/24/2018
On Market Since
5/24/2018
Pharmacological Classes
Price Statistics
The NADAC for PROGRAF 0.2 MG GRANULE PACKET has been published 81 times since Mar 19, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.0151 per EA |
|---|---|
| All-time high | $5.0287 (Aug 13, 2025) |
| All-time low | $5.0042 (Aug 19, 2026) |
| 52-week high | $5.0151 |
| 52-week low | $5.0042 |
| Median price | $5.0053 |
| Average price | $5.0126 |
| Largest weekly change | -0.5% (Aug 20, 2025) |
| Weeks tracked | 81 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Tacrolimus market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Astellas Pharma US, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tacrolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PROGRAF 0.2 MG GRANULE PACKET?
The current National Average Drug Acquisition Cost (NADAC) for PROGRAF 0.2 MG GRANULE PACKET, manufactured by Astellas Pharma US, Inc., is $5.0151 per EA (NDC 00469123050), effective Sep 30, 2026.
How has the price of PROGRAF 0.2 MG GRANULE PACKET changed over time?
Over the history we have for it, the NADAC for PROGRAF 0.2 MG GRANULE PACKET has held within roughly two percent of its current level. It has been tracked across 81 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for PROGRAF 0.2 MG GRANULE PACKET?
Since Mar 19, 2025, the NADAC for PROGRAF 0.2 MG GRANULE PACKET has ranged from a low of $5.0042 (Aug 19, 2026) to a high of $5.0287 (Aug 13, 2025), with a median of $5.0053 per EA.
Are there cheaper alternatives to PROGRAF 0.2 MG GRANULE PACKET?
No other NADAC-published product currently shares the active ingredient and strength of PROGRAF 0.2 MG GRANULE PACKET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PROGRAF 0.2 MG GRANULE PACKET?
PROGRAF 0.2 MG GRANULE PACKET (NDC 00469123050) is labeled by Astellas Pharma US, Inc., and CMS classifies it as a brand product.